HarmonEyes Acquires iFocus Health too Revolutionize ADHD Medication Management with AI-Powered Eye Tracking
HarmonEyes, a leading innovator in AI-driven eye-tracking software, has finalized the acquisition of iFocus Health, a clinically validated solution for objectively monitoring ADHD treatment response. This strategic move promises to transform how clinicians assess and personalize medication for the millions affected by Attention-deficit/Hyperactivity disorder.
The acquisition, announced on December 10, 2025, addresses a critical gap in ADHD care: the reliance on subjective assessments. Traditionally, determining the efficacy of ADHD medication has depended on patient self-reports, behavioral checklists, and clinician observation – methods frequently enough prone to bias and guesswork. iFocus Health’s platform offers a paradigm shift by tracking subtle changes in eye movement during everyday activities, such as reading, providing clinicians with objective, actionable data.
“ADHD isn’t just about distraction; it’s about underperformance in a world that demands focus. But until now, we’ve lacked tools that effectively measure treatment efficacy in real time,” stated a senior official from iFocus Health. “Under HarmonEyes, we’re combining our missions with a powerful technology engine that can scale this capability to millions more people. It’s a major step forward for ADHD care.”
Now operating as HarmonEyes Focus, the acquired technology will be integrated into HarmonEyes’ broader mission of leveraging eye movement as a window into human performance. HarmonEyes’ existing AI models already deliver real-time insights into cognitive and emotional states, and iFocus adds a crucial layer focused on measuring and improving responses to ADHD treatment. this technology has potential applications extending beyond healthcare,into education and everyday life,all aimed at a deeper understanding of brain function and optimized performance.
The need for more objective ADHD treatment monitoring is significant. according to data from the Centers for Disease control and Prevention (CDC), approximately 6 million children and 16 million adults in the United States have been diagnosed with ADHD. Despite these high numbers, medication management often remains reliant on less-than-ideal methods.
HarmonEyes Focus offers a data-driven option, providing clinicians with a real-time view of medication effectiveness. This allows for more precise adjustments to dosage,timing,and treatment type,reducing uncertainty and increasing confidence in care decisions. This approach aligns with HarmonEyes’ existing work in real-time cognitive state detection across various industries.
“This acquisition reflects a core part of our strategy to build the world’s first foundational model for eye-tracking to understand the human state,” explained adam Gross, CEO and co-founder of HarmonEyes. “iFocus brings a proven and relevant use case that fits perfectly within our broader vision. By combining their objective approach to measure the effectiveness of ADHD treatment with our real-time eye-tracking AI platform, we are unlocking new ways to support focus, readiness, and mental performance across many areas of life.”
The acquisition signals a growing trend toward objectivity in human decision-making. The platform’s potential extends beyond ADHD, with possibilities for supporting othre neurodivergent conditions, optimizing performance in educational and professional settings, and enhancing focus and recovery in clinical environments. .
For more information about HarmonEyes and its eye-tracking solutions, visit www.harmoneyes.com.
About HarmonEyes
HarmonEyes is positioned as the world’s only open,AI-powered eye-tracking platform capable of identifying and predicting a person’s cognitive,emotional,and physical state based solely on eye movements. Compatible with any camera-based device, HarmonEyes provides a extensive solution for analyzing eye-tracking data, developing custom models, and deploying applications at scale using the Theia™ SDK. With over 60 years of eye-tracking experience and a database of 14 million unique records, HarmonEyes serves leading organizations in technology, aviation/automotive, healthcare, and elite performance sectors. Learn more and request a demo at www.harmoneyes.com.
Media inquiries can be directed to Lightspeed PR at [email protected].
SOURCE HarmonEyes
